Cancer Therapy Market Size, Share, Forecast & Trends Analysis by Therapy Class, Molecule Type, Route of Administration, Line of Therapy, Cancer Indication, Treatment Setting, Distribution Channel, End User, and Geography - Global Forecast to 2036

The global cancer therapy market was valued at USD 221.50 billion in 2025. It is estimated at USD 240.00 billion in 2026 and is projected to reach USD 472.10 billion by 2036, growing at a CAGR of 7.0% over the 2026-2036 forecast period. This report assesses the market in depth, covering epidemiology, treatment paradigms, modality trends, the pipeline, patent expiry, pricing and reimbursement, regulation, manufacturing and isotope supply, licensing and M&A, and competition.

The study covers approved medicines and biologics used to treat cancer: targeted therapy, immunotherapy (including checkpoint inhibitors, bispecific antibodies, cell therapies, cancer vaccines, and oncolytic viruses), chemotherapy, hormonal therapy, and radioligand therapy. The market is measured at manufacturer sales. Radiotherapy equipment and services, surgery, diagnostics and companion testing, and supportive care drugs such as antiemetics are outside the scope.

According to the International Agency for Research on Cancer (IARC), there were about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and annual new cases are projected to exceed 35 million by 2050. Value in the market is highly concentrated: Merck reported Keytruda sales of USD 31,680 million in 2025, and the company expects its main U.S. patent to expire in 2028, with government price setting taking effect from January 2029. Newer modalities are scaling quickly: Johnson & Johnson reported 2025 Oncology sales of USD 25,380 million, up 22.1%, and the company reported that sales of its CAR-T therapy Carvykti rose 95.9%.

Market Dynamics

Cancer risk rises sharply with age, so aging populations in North America, Europe, and East Asia add patients each year, while longer survival means many patients receive several lines of treatment. Antibody-drug conjugates and bispecific antibodies are moving from late-line use into first- and second-line treatment, which enlarges the eligible population and lengthens time on therapy. Routine tumor sequencing directs more patients to biomarker-matched drugs, cell and radioligand therapies have become commercial modalities with high per-patient value, and wider reimbursement in China, India, Brazil, Mexico, and the Gulf states is bringing more patients into treatment.

The largest checkpoint inhibitors and monoclonal antibodies begin losing exclusivity in 2028, and biosimilars will sharply reduce revenue per patient even as volumes hold. Price negotiation in the U.S., health technology assessment in Europe, and volume-based procurement in China all weigh on realized prices. Patient-specific cell therapy manufacturing and limited isotope capacity slow scale-up, and late-stage trial failures remain costly. Further challenges include crowding around targets such as PD-1/PD-L1, HER2, TROP2, and BCMA, cross-resistance when similar drugs are given in sequence, few accredited centers for complex therapies, and the toxicity of combination regimens.

Opportunities lie in subcutaneous and oral reformulation of established biologics, radioligands for new tumor targets using alpha emitters such as actinium-225, allogeneic and in vivo cell therapy platforms, and biosimilars that reach untreated patients in emerging markets. Merck's subcutaneous Keytruda Qlex, approved by the U.S. FDA in September 2025, is protected in the U.S. until 2043. Key trends include the shift from infusion to subcutaneous dosing, earlier use of advanced modalities, the rise of Chinese biotech companies as a source of licensed assets, and the development of drugs as parts of combination regimens.

Segment Analysis

The report analyzes the market by therapy class, molecule type, route of administration, line of therapy, cancer indication, treatment setting, distribution channel, end user, and geography, helping stakeholders identify where demand and value are shifting.

By therapy class, the report covers targeted therapy, immunotherapy, chemotherapy, hormonal therapy, and radiopharmaceutical therapy. Targeted therapy is expected to hold the largest share in 2026, as kinase inhibitors, monoclonal antibodies, and antibody-drug conjugates are used across many solid tumors and blood cancers, often after biomarker testing that supports premium pricing. Radiopharmaceutical therapy is expected to grow at the highest CAGR, as radioligands expand beyond prostate and neuroendocrine cancers, alpha-emitter supply is scaled up, and large drug makers enter the field through acquisitions. Immunotherapy remains central, though branded checkpoint inhibitor revenue faces pressure from 2028.

By molecule type, the study examines monoclonal antibodies, antibody-drug conjugates, bispecific antibodies & T-cell engagers, small molecules, cell & gene therapies, and radioligands. Monoclonal antibodies are expected to lead in 2026, reflecting the scale of checkpoint inhibitors such as Keytruda and established antibodies such as Darzalex, which also serve as backbones of combination regimens. Cell & gene therapies are expected to grow at the highest CAGR, as CAR-T products such as Carvykti move into earlier lines of multiple myeloma treatment and manufacturing capacity expands.

The route of administration analysis spans intravenous, subcutaneous, oral, and intratumoural & other routes. Intravenous delivery is expected to hold the largest share in 2026, since checkpoint inhibitors, most antibodies, conjugates, and chemotherapy are infused and make up most treated volume. The subcutaneous route is expected to grow at the highest CAGR, driven by reformulated antibodies such as Keytruda Qlex that extend patent life, take minutes to give, and free infusion chairs.

By line of therapy, the report covers first line, second line, third line & later, and adjuvant & neoadjuvant use. First-line treatment is expected to hold the largest share in 2026, because checkpoint inhibitors and targeted agents are standard initial therapy in major solid tumors with the largest eligible patient pools. The adjuvant & neoadjuvant segment is expected to grow at the highest CAGR, as new approvals bring advanced modalities into early-stage disease to prevent recurrence in far larger populations.

The cancer indication analysis includes lung cancer, breast cancer, haematological malignancies, gastrointestinal cancers, genitourinary cancers, gynaecologic cancers, and other cancers. Lung cancer is expected to represent the largest share in 2026, owing to its high incidence and heavy use of checkpoint inhibitors and mutation-matched targeted drugs. Haematological malignancies are expected to grow at the highest CAGR, driven by bispecific antibodies and CAR-T therapies in multiple myeloma, lymphoma, and leukemia, where patients receive several advanced therapies in sequence. Breast cancer remains a major indication as conjugates widen options across HER2-positive, HER2-low, and triple-negative disease.

By treatment setting, the study covers hospital inpatient care, hospital outpatient & infusion centers, specialty cancer centers, and community oncology practices. Hospital outpatient & infusion centers are expected to lead in 2026, as most intravenous cancer drugs are given in outpatient infusion units. Specialty cancer centers are expected to grow at the highest CAGR, since cell and radioligand therapies require accredited sites with apheresis, cryogenic storage, intensive care support, and nuclear medicine facilities.

By distribution channel, the report covers hospital pharmacies, specialty pharmacies, and retail pharmacies. Hospital pharmacies handle infused products and the complex logistics of cell and radioligand therapies, specialty pharmacies dispense high-cost oral targeted drugs and manage payer approval and patient support, and retail pharmacies mainly supply oral hormonal agents and generics. The move toward oral and subcutaneous products is expected to raise the role of channels outside the hospital.

The end user analysis covers hospitals & cancer centers, specialty clinics, and home & ambulatory care. Hospitals & cancer centers are expected to hold the largest share in 2026, as they have the infusion capacity, monitoring, and staff needed to manage side effects across all therapy classes. Home & ambulatory care is expected to grow at the highest CAGR, supported by oral targeted drugs and short subcutaneous injections that allow treatment outside the hospital.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Southeast Asia, and four rest-of-region groups. The analysis considers incidence, approval timing, reimbursement, treatment infrastructure, and patent expiry timing in each market.

North America is expected to remain the largest regional market in 2026, as the U.S. receives most new oncology drugs first, pays the highest prices, has broad insurance coverage, and is home to many leading developers, although it is also where value erosion starts first, with Keytruda facing U.S. patent expiry in 2028 and price setting from 2029. Europe holds a significant share, led by Germany, France, Italy, Spain, and the U.K., with Keytruda protection lasting to 2031, although health technology assessment delays or limits uptake of some therapies.

Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by large and rising patient numbers, expanding reimbursement, and its growing role as a source of new drugs. Chinese developers license conjugate, bispecific, and cell therapy assets to global companies, Japan hosts leading conjugate developers, and South Korea and India pair rising demand with biosimilar production. In Latin America, Brazil and Mexico are the largest markets and biosimilar entry should widen access, while in the Middle East & Africa, Gulf states are investing in comprehensive cancer centers and adopting advanced therapies early.

Competitive Landscape

The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, strategic developments, and 2025 market share/rank analysis, with company profiles covering business overview, financials, product portfolio, recent developments, and SWOT analysis.

The market is led by large pharmaceutical companies with portfolios across several therapy classes, alongside cell therapy and radiopharmaceutical specialists, Chinese biotech companies licensing assets abroad, and biosimilar makers preparing for patent expiries. Keytruda is the largest single product, while Johnson & Johnson's oncology portfolio, led by Darzalex and Carvykti, is among the fastest growing. Main strategies include label expansion into first-line and adjuvant use, subcutaneous conversion of antibodies, acquisition and licensing of conjugate, bispecific, and radiopharmaceutical assets, and investment in cell therapy and isotope capacity, as seen in the 2025 U.S. approval of Keytruda Qlex.

Key companies profiled in the report include Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca PLC (U.K.), Bristol Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Sanofi S.A. (France), GSK plc (U.K.), Daiichi Sankyo Company, Limited (Japan), Gilead Sciences, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Regeneron Pharmaceuticals, Inc. (U.S.), Genmab A/S (Denmark), Legend Biotech Corporation (China/U.S.), Advanced Accelerator Applications (Novartis) (France), BeiGene, Ltd. (BeOne Medicines) (China/Switzerland), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China).

How This Report Helps

• Provides reliable market size estimates and long-term forecasts for the global cancer therapy market through 2036.
• Explains how rising incidence, earlier use of conjugates and bispecifics, and precision oncology are shaping demand.
• Assesses the impact of patent expiry, biosimilars, government price setting, and health technology assessment on market value.
• Identifies high-growth opportunities across therapy class, molecule type, route, line of therapy, indication, setting, channel, end user, and region.
• Tracks emerging modalities such as alpha-emitting radioligands, allogeneic and in vivo cell therapies, and subcutaneous reformulations.
• Benchmarks leading companies on portfolios, pipelines, licensing and acquisition activity, and market position.
• Supports portfolio planning, business development, market access, and investment decisions for drug developers, investors, and providers.

Key Questions Answered

• How large is the global cancer therapy market today, and how will it grow through 2036?
• How will the loss of exclusivity on Keytruda and other major biologics affect market value from 2028?
• What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
• How quickly are conjugates, bispecifics, cell therapies, and radioligands moving into earlier lines of treatment?
• Which therapy class, molecule type, route, line of therapy, indication, and care setting will grow the fastest?
• How are subcutaneous reformulation and biosimilar entry changing the economics of established biologics?
• Which regions and countries offer the most attractive opportunities, and how is China's role in oncology changing?
• Who are the leading companies in the market, and how do they compare?
• What approvals, licensing deals, acquisitions, and capacity investments are shaping competition?